Abstract
Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14%), five PR (12%), thirteen SD (31%) and seventeen PD (41%) were observed for an overall response rate of 26%. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 3045-3052 |
| Number of pages | 8 |
| Journal | Anticancer Research |
| Volume | 22 |
| Issue number | 5 |
| Publication status | Published - Sep 2002 |
Fingerprint
Keywords
- C-reactive protein
- Immunotherapy
- Interleukin-2
- Interleukin-6
- Medroxyprogesterone acetate
- Renal cell carcinoma
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma. / Naglieri, Emanuele; Lopez, Massimo; Lelli, Giorgio; Morelli, Francesco; Amodio, Antonella; di Tonno, Pasquale; Gebbia, Nicola; Di Seri, Marisa; Concetta Chetri, Maria; Rizzo, Pietro; Abbate, Ines; Casamassima, Addolorata; Paolo Selvaggi, Francesco; Colucci, Giuseppe.
In: Anticancer Research, Vol. 22, No. 5, 09.2002, p. 3045-3052.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interleukin-2, interferon-α and medroxyprogesterone acetate in metastatic renal cell carcinoma
AU - Naglieri, Emanuele
AU - Lopez, Massimo
AU - Lelli, Giorgio
AU - Morelli, Francesco
AU - Amodio, Antonella
AU - di Tonno, Pasquale
AU - Gebbia, Nicola
AU - Di Seri, Marisa
AU - Concetta Chetri, Maria
AU - Rizzo, Pietro
AU - Abbate, Ines
AU - Casamassima, Addolorata
AU - Paolo Selvaggi, Francesco
AU - Colucci, Giuseppe
PY - 2002/9
Y1 - 2002/9
N2 - Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14%), five PR (12%), thirteen SD (31%) and seventeen PD (41%) were observed for an overall response rate of 26%. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.
AB - Background: Interleukin-2 (IL-2) and interferon-α (IFN-α) are the main immuno-biological agents used in the therapy of metastatic renal cell carcinoma (RCC). Unfortunately the promising results obtained in biological studies have not yet been confirmed in clinical studies. One reason is linked to the immunosuppression of metastatic patients which is caused by macrophage products. IL-6 in particular is considered a growth factor for RCC. Medroxyprogesterone acetate (MPA) may interfere with IL-6 macrophage production, possibly causing a synergistic effect in association with IL-2 and IFN-α. Therefore the purpose of our study was to evaluate the toxicity and the efficacy of the association between IL-2, IFN-α and MPA. Patients and Methods: Forty-two consecutive patients with metastatic RCC were enrolled. IL-2 was administered subcutaneously at doses of 4.5 million UI on days 1-5, 8-12, 15-19 and 22-26; IFN-α was administered s.c. at a dose of 3 million t.t.w; MPA was administered orally at a dose of 1000 mg daily. This schedule was repeated after a rest of 2 weeks. Results: Toxicity was mild: the main symptoms observed were fatigue and fever. Six CR (14%), five PR (12%), thirteen SD (31%) and seventeen PD (41%) were observed for an overall response rate of 26%. Patients with good PS and low levels of CRP had a better prognosis. Conclusion: Considering both the good activity and the low toxicity of this scheme, we think that it could be carried out in normal clinical practice.
KW - C-reactive protein
KW - Immunotherapy
KW - Interleukin-2
KW - Interleukin-6
KW - Medroxyprogesterone acetate
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0036765649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036765649&partnerID=8YFLogxK
M3 - Article
C2 - 12530040
AN - SCOPUS:0036765649
VL - 22
SP - 3045
EP - 3052
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5
ER -